Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome
PROSP_BRUGANAE
BRUGADA-ANAESTHESIA Registry: Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome
1 other identifier
observational
200
1 country
1
Brief Summary
The goal of this observational study is to evaluate the perioperative risk of malignant ventricular arrhythmias in adult patients diagnosed with Brugada Syndrome undergoing anaesthetic procedures. Brugada Syndrome is a rare inherited cardiac condition associated with an increased risk of life-threatening arrhythmias, and perioperative management remains challenging due to limited high-quality evidence. The main questions it aims to answer are:
- What is the incidence of malignant ventricular arrhythmias during anaesthesia and up to 30 days after the procedure?
- Are anaesthetic drugs traditionally considered "non-recommended" associated with an increased risk of perioperative arrhythmic events? Researchers will also explore the relative contribution of anaesthetic drugs versus perioperative physiological factors (e.g., haemodynamic changes, fever, bradycardia) in triggering arrhythmias. Participants will:
- Undergo anaesthetic procedures (general, locoregional, or sedation) as part of routine clinical care
- Have clinical data collected prospectively from electronic medical records during the perioperative period
- Be followed for 30 days after the procedure to assess outcomes, including arrhythmias, complications, ICU admission, and mortality This is a multicentre, prospective observational registry, and no additional interventions or changes to standard clinical practice will be performed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 9, 2026
CompletedFirst Posted
Study publicly available on registry
June 17, 2026
CompletedStudy Start
First participant enrolled
July 20, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2028
Study Completion
Last participant's last visit for all outcomes
December 20, 2028
June 17, 2026
April 1, 2026
1.9 years
June 9, 2026
June 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of cardiac arrhytmia from the start of anaesthesia/sedation until 24 hours after the procedure
To determine the incidence of sustained ventricular tachycardia, ventricular fibrillation, arrhythmic cardiac arrest, aborted sudden cardiac death, or appropriate ICD therapy for ventricular arrhythmia from the start of anaesthesia/sedation until 24 hours after the procedure.
24 hours
Secondary Outcomes (4)
Intraoperative anesthetic management strategies in BrS patients
During the anesthesic procedure
Peri-procedural complications and relevant ECG changes
During the anesthesic procedure
Periprocedural complications
Perioperative
30 days outcome
30 days after the anesthesic procedure
Study Arms (1)
Brugada Syndrome Patients Undergoing Anaesthesia
Adult patients (≥18 years) with a confirmed diagnosis of Brugada Syndrome undergoing anaesthetic procedures (general, locoregional, or sedation) for surgical or non-surgical interventions. This is an observational cohort with no assigned interventions. Anaesthetic management, including the use of specific drugs (e.g., propofol, local anaesthetics, ketamine), will be performed according to routine clinical practice. Participants will be followed during the perioperative period and up to 30 days after the procedure to assess the occurrence of malignant ventricular arrhythmias and other clinical outcomes.
Eligibility Criteria
The study population will consist of adult patients with a confirmed diagnosis of Brugada Syndrome receiving care at participating tertiary and secondary hospitals. Patients will be identified through preoperative anaesthesia assessments, hospital admissions, and operating room schedules. The registry will include consecutive patients undergoing any type of anaesthetic procedure (general, locoregional, or sedation) for surgical or non-surgical interventions as part of routine clinical care. Participating centres are expected to include institutions with experience in the perioperative management of cardiac patients, ensuring representation of real-world clinical practice across different healthcare settings.
You may qualify if:
- Documented type 1 Brugada ECG pattern (spontaneous, fever-related, or induced by sodium-channel blocker challenge/other recognised provocation test) with a diagnosis considered compatible with Brugada syndrome by the treating cardiology team.
- Undergoing general anaesthesia, monitored sedation, loco-regional anaesthesia for any surgical, diagnostic, interventional, obstetric or other non-surgical procedure (including epidural analgesia for labour and sedation for endoscopy).
You may not qualify if:
- No documented type 1 Brugada ECG pattern, uncertain diagnosis without sufficient supporting data.
- Refusal to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Clinic de Barcelona
Barcelona, Barcelona, 08036, Spain
Related Publications (13)
Espinosa A, Ripolles-Melchor J, Brugada R, Campuzano O, Sarquella-Brugada G, Abad-Motos A, Zaballos-Garcia M, Abad-Torrent A, Prieto-Gundin A, Brugada J. Brugada Syndrome: anesthetic considerations and management algorithm. Minerva Anestesiol. 2019 Feb;85(2):173-188. doi: 10.23736/S0375-9393.18.13170-1. Epub 2018 Oct 30.
PMID: 30394071BACKGROUNDOjaimi RE, Carteron M, Arnold S, Broux N, Corsia G, Zicarelli JP, Benhamou D. Neuraxial anesthesia for delivery in parturtients with Brugada syndrome: Local anesthetics revisited. J Gynecol Obstet Hum Reprod. 2023 May;52(5):102562. doi: 10.1016/j.jogoh.2023.102562. Epub 2023 Feb 27. No abstract available.
PMID: 36858196BACKGROUNDRipley A, Castro J, Gadsden J. Local anesthetics, neuraxial anesthesia, and the Brugada syndrome. J Clin Anesth. 2013 Feb;25(1):78-9. doi: 10.1016/j.jclinane.2012.06.012. Epub 2012 Dec 12. No abstract available.
PMID: 23246496BACKGROUNDCole JB, Sattiraju S, Bilden EF, Asinger RW, Bertog SC. Isolated tramadol overdose associated with Brugada ECG pattern. Pacing Clin Electrophysiol. 2012 Aug;35(8):e219-21. doi: 10.1111/j.1540-8159.2010.02924.x. Epub 2010 Oct 7.
PMID: 21039643BACKGROUNDRollin A, Maury P, Guilbeau-Frugier C, Brugada J. Transient ST elevation after ketamine intoxication: a new cause of acquired brugada ECG pattern. J Cardiovasc Electrophysiol. 2011 Jan;22(1):91-4. doi: 10.1111/j.1540-8167.2010.01766.x.
PMID: 20384648BACKGROUNDCuttone G, Martucci G, Napoli R, Tigano S, Arcadipane A, Pappalardo F, Sanfilippo F. Anesthesiological management of Brugada syndrome patients: A systematic review. Saudi J Anaesth. 2023 Jul-Sep;17(3):394-400. doi: 10.4103/sja.sja_205_23. Epub 2023 Jun 22.
PMID: 37601502BACKGROUNDDuque M, Santos L, Ribeiro S, Catre D. Anesthesia and Brugada syndrome: a 12-year case series. J Clin Anesth. 2017 Feb;36:168-173. doi: 10.1016/j.jclinane.2016.09.031. Epub 2016 Dec 7.
PMID: 28183560BACKGROUNDFlamee P, Viaene K, Tosi M, Nogueira Carvalho H, de Asmundis C, Forget P, Poelaert J. Propofol for Induction and Maintenance of Anesthesia in Patients With Brugada Syndrome: A Single-Center, 25-Year, Retrospective Cohort Analysis. Anesth Analg. 2021 Jun 1;132(6):1645-1653. doi: 10.1213/ANE.0000000000005540.
PMID: 33857025BACKGROUNDFlamee P, Varnavas V, Dewals W, Carvalho H, Cools W, Bhutia JT, Beckers S, Umbrain V, Verborgh C, Forget P, Chierchia GB, Brugada P, Poelaert J, de Asmundis C. Electrocardiographic Effects of Propofol versus Etomidate in Patients with Brugada Syndrome. Anesthesiology. 2020 Mar;132(3):440-451. doi: 10.1097/ALN.0000000000003030.
PMID: 31743136BACKGROUNDPostema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009 Sep;6(9):1335-41. doi: 10.1016/j.hrthm.2009.07.002. Epub 2009 Jul 8.
PMID: 19716089BACKGROUNDBorrell-Vega J, Fernandez Font JD, Linares M, Martinez-Palli G, Isabel-Roquero A, Mont L, Brugada J, Arbelo E, Gimenez-Mila M. Eighteen-year analysis of anaesthetic management in Brugada syndrome: The BRUGANAES study. Eur J Anaesthesiol. 2025 May 1;42(5):458-467. doi: 10.1097/EJA.0000000000002146. Epub 2025 Feb 12.
PMID: 39945140BACKGROUNDBrugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present Status of Brugada Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018 Aug 28;72(9):1046-1059. doi: 10.1016/j.jacc.2018.06.037.
PMID: 30139433BACKGROUNDBrugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992 Nov 15;20(6):1391-6. doi: 10.1016/0735-1097(92)90253-j.
PMID: 1309182BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 30 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 9, 2026
First Posted
June 17, 2026
Study Start (Estimated)
July 20, 2026
Primary Completion (Estimated)
May 31, 2028
Study Completion (Estimated)
December 20, 2028
Last Updated
June 17, 2026
Record last verified: 2026-04